Page last updated: 2024-11-13

rka 182

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

RKA 182: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46701727
CHEMBL ID2387268
MeSH IDM0553242

Synonyms (3)

Synonym
CHEMBL2387268
2-dispiro[[?]]yl-1-[4-(4-methylpiperazin-1-yl)-1-piperidyl]ethanone
rka 182
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1873060Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as inhibition of parasite growth preincubated with compound for 24 hrs followed by hypoxanthine addition and measured after 24 hrs by [3H]2022European journal of medicinal chemistry, Jul-05, Volume: 237Spiral molecules with antimalarial activities: A review.
AID1873061Antimalarial activity against chloroquine resistant Plasmodium falciparum K1 infected in human erythrocyte assessed as inhibition of parasite growth preincubated with compound for 24 hrs followed by hypoxanthine addition and measured after 24 hrs by [3H]-2022European journal of medicinal chemistry, Jul-05, Volume: 237Spiral molecules with antimalarial activities: A review.
AID748926Antiplasmodial activity against drug-sensitive Plasmodium falciparum 3D72013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID748922Antimalarial activity against Plasmodium infected in mouse2013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1873108Antimalarial activity against Plasmodium berghei GFP ANKA infected in NMRI mouse assessed as reduction in blood parasitemia level measured on day 4 by FACS analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Spiral molecules with antimalarial activities: A review.
AID1496854Half life in Sprague-Dawley rat at 10 mg/kg, po2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID748923Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1496713Antimalarial activity against Plasmodium berghei infected in mouse assessed as mouse mean survival days at 30 mg/kg, po administered as single dose2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID748924Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum K12013Bioorganic & medicinal chemistry letters, May-15, Volume: 23, Issue:10
Recent advances in malaria drug discovery.
AID1496712Antimalarial activity against Plasmodium berghei infected in mouse assessed as reduction in parasitemia at 30 mg/kg, po administered as single dose measured on day 3 relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
AID1057260Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D72013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]